Affordable Access

Access to the full text

Glioma SOX2 expression decreased after adjuvant therapy

Authors
  • Yu, Wei1, 2
  • Ren, Xiaoqiu1, 2
  • Hu, Chunxiu1, 3
  • Tan, Yinuo4
  • Shui, Yongjie1
  • Chen, Zexin5
  • Zhang, Lili1, 2
  • Peng, Jiaping1, 2
  • Wei, Qichun1, 2
  • 1 Zhejiang University School of Medicine, Department of Radiation Oncology, the Second Affiliated Hospital, Jiefang Road 88, Hangzhou, 310009, People’s Republic of China , Hangzhou (China)
  • 2 Zhejiang University Cancer Institute, Cancer Institute (Ministry of Education Key Laboratory of Cancer Prevention and Intervention), Hangzhou, 310009, People’s Republic of China , Hangzhou (China)
  • 3 Department of Radiation Oncology, Zhejiang Quhua Hospital, Quzhou, 324000, People’s Republic of China , Quzhou (China)
  • 4 Zhejiang University School of Medicine, Department of Medical Oncology, the Second Affiliated Hospital, Hangzhou, 310009, People’s Republic of China , Hangzhou (China)
  • 5 Zhejiang University School of Medicine, Center of Clinical Epidemiology and Biostatistics for statistical analysis, the Second Affiliated Hospital, Hangzhou, 310009, People’s Republic of China , Hangzhou (China)
Type
Published Article
Journal
BMC Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Nov 12, 2019
Volume
19
Issue
1
Identifiers
DOI: 10.1186/s12885-019-6292-y
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundSOX2 is regarded as an important marker in stem cell. The change of SOX2 expression after adjuvant therapy in high grade glioma (HGG) remains unknown so far. Few patients with recurrent glioma have opportunity to undergo operation once again, so the recurrent glioma samples are scarce. This study tries to analyze SOX2 expression in paired primary and recurrent HGG, aims to better understand the transformation law of SOX2 after adjuvant therapy in HGG.MethodsTwenty-four recurrent HGG patients who undergone a second resection were included. 16 patients received adjuvant therapy, the remaining 8 patients didn’t receive any adjuvant therapy at all. The protein expression of SOX2 in paired primary and recurrent HGG was tested by immunohistochemistry. The statistical analysis was conducted by IBM SPSS Statistics 19.0.ResultsIn primary HGG, SOX2 expression of 3 + , 2 + , 1+ and 0+ were seen in 20 (83.3%), 1 (4.2%), 1 (4.2%) and 2 cases (8.3%), respectively. The expression of SOX2 was decreased in recurrent HGG compared to the paired primary sample (p = 0.001). The decrease of SOX2 was often seen in patients received chemotherapy, radiotherapy or both (p = 0.003). Patients with SOX2 high expression in primary glioma had a longer median PFS than those with SOX2 low expression with marginal statistic significance (12.7 vs. 5.4 months, p = 0.083). For cases with SOX2 high expression in the primary glioma, those had SOX2 low expression after recurrence seemed to have worse prognosis as compared to patients with stable SOX2 high expression (PFS: 10.4 vs. 14.9 months, p = 0.036; OS: 27.0 vs 49.5 months, p = 0.005).ConclusionsThis is the first study comparing the protein expression of SOX2 in recurrent HGG and its paired primary tumor. SOX2 high expression is common in brain HGG, a tendency of decreased SOX2 expression in recurrent gliomas was evidenced. Lower SOX2 expression was seen in those patients who received adjuvant chemotherapy and/or radiotherapy. Patients with low SOX2 expression in primary HGG usually have poorer prognosis, those with SOX2 expression decreased in recurrent HGG had worse outcome.

Report this publication

Statistics

Seen <100 times